← Browse by Condition
Medical Condition

pancreatic neuroendocrine tumor

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for pancreatic neuroendocrine tumor sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — pancreatic neuroendocrine tumor Clinical Trials

How many clinical trials are currently recruiting for pancreatic neuroendocrine tumor?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for pancreatic neuroendocrine tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for pancreatic neuroendocrine tumor?
pancreatic neuroendocrine tumor research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a pancreatic neuroendocrine tumor clinical trial?
Eligibility criteria for pancreatic neuroendocrine tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Shanghai Jiao Tong University School of Medicine 1 trial
IRCCS San Raffaele 1 trial
Merck Sharp & Dohme LLC 1 trial

Recruiting Clinical Trials

NCT06141369
Recruiting
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Enrollment
21 pts
Location
China
Sponsor
Shanghai Jiao Tong University ...
View Trial →
NCT06121622
Recruiting
Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours
Enrollment
70 pts
Location
Italy
Sponsor
IRCCS San Raffaele
View Trial →
NCT04924075 Phase 2
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Enrollment
355 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
View Trial →

Related Conditions

adrenal cortical carcinoma (1) medullary thyroid cancer (1) thymic neuroendocrine carcinoma (1) pheochromocytoma paraganglioma (1) von hippel lindau disease (1) advanced gastrointestinal stromal tumor (1) hif 2 mutated cancers (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology